Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the transarterial chemoperfusion treatment
with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant
pleural mesothelioma (MPM).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute